TissGeneSummary for PCSK4 |
Gene summary |
Basic gene information | Gene symbol | PCSK4 |
Gene name | proprotein convertase subtilisin/kexin type 4 | |
Synonyms | PC4|SPC5 | |
Cytomap | UCSC genome browser: 19p13.3 | |
Type of gene | protein-coding | |
RefGenes | NM_017573.4, | |
Description | - | |
Modification date | 20141207 | |
dbXrefs | MIM : 600487 | |
HGNC : HGNC | ||
Ensembl : ENSG00000115257 | ||
Vega : OTTHUMG00000128541 | ||
Protein | UniProt: go to UniProt's Cross Reference DB Table | |
Expression | CleanEX: HS_PCSK4 | |
BioGPS: 54760 | ||
Pathway | NCI Pathway Interaction Database: PCSK4 | |
KEGG: PCSK4 | ||
REACTOME: PCSK4 | ||
Pathway Commons: PCSK4 | ||
Context | iHOP: PCSK4 | |
ligand binding site mutation search in PubMed: PCSK4 | ||
UCL Cancer Institute: PCSK4 | ||
Assigned class in TissGDB* | B | |
Included tissue-specific gene expression resources | HPA,TiGER,GTEx | |
Specific-tissues in normal samples (assigned by TissGDB using HPA, TiGER, and GTEx) | Testis | |
Cancer types related to the specific-tissues in cancer samples (assigned by TissGDB using TCGA) | TGCT | |
Reference showing the relevant tissue of PCSK4 | ||
Description by TissGene annotations | TissgsLTS |
* Class A consists of genes with literature evidence and is part of the cTissGenes. Class B consists of only cTissGenes without additional evidence. The remaining genes belong to Class C. |
Gene ontology having evidence of Inferred from Direct Assay (IDA) from Entrez |
GO ID | GO term | PubMed ID |
Top |
TissGeneExp for PCSK4 |
Gene expressions across 28 cancer types (X-axis: cancer type and Y-axis: log2(norm_counts+1)) (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) |
Gene isoform expressions across 28 cancer types (X-axis: cancer type and Y-axis: log2(norm_counts+1)) (TCGA pan-cancer tcga_rsem_isoform_tpm, version 2016-09-01) |
Gene expressions across normal tissues of GTEx data (GTEx GTEx_Analysis_v6_RNA-seq_RNA-SeQCv1.1.8_gene_rpkm.gct) - Here, we shows the matched tissue types only among our 28 cancer types. |
Different expressions across 14 cancer types with more than 10 samples between matched tumors and normals (X-axis: cancer type and Y-axis: log2(norm_counts+1)) (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) |
- Significantly differentially expressed cancer types and information. (|Fold change|>1 and FDR<0.05) |
Cancer type | Mean(exp) in tumor | Mean(exp) in matched normal | Log2FC | P-val. | FDR |
BLCA | -0.87979615 | -2.008627729 | 1.128831579 | 0.0105 | 0.046797595 |
Top |
TissGene-miRNA for PCSK4 |
Significantly anti-correlated miRNAs of TissGene across 28 cancer types (Gene-miRNA relations from TargetScanHuman Relsease 7.1, Conserved_Site_Context_Scores.txt.zip, 06.01.2016) (TCGA IlluminaHiSeq_miRNASeq, log2(RPM+1) data, version 2016-11-21) (TCGA IlluminaHiSeq_RNASeqV2, log2(normalized_count+1) data, version 2016-08-16) (Spearman’s Rank Correlation (p-value<0.05 and coefficient<-0.25)) |
Cancer type | miRNA id | miRNA accession | P-val. | Coeff. | # samples |
Top |
TissGeneMut for PCSK4 |
TissGeneSNV for PCSK4 |
nsSNV counts per each loci. Different colors of circles represent different cancer types. Circle size denotes number of samples. (TCGA somatic mutation (SNPs and small INDELs) data, version 2016-04-25) * Click on the image to enlarge it in a new window. |
Somatic nucleotide variants of TissGene across 28 cancer types (X-axis: cancer type and Y-axis: % of mutated samples) The numbers in parentheses are numbers of samples with mutation (nsSNVs). (TCGA somatic mutation (SNPs and small INDELs) data, version 2016-04-25) |
- nsSNVs sorted by frequency. |
AAchange | Cancer type | # samples |
p.A204V | UCEC | 1 |
p.C596Y | COAD | 1 |
p.R113H | STAD | 1 |
p.G272C | LUAD | 1 |
p.G726D | PRAD | 1 |
p.R739C | KIRP | 1 |
p.M729I | STAD | 1 |
p.R276C | CESC | 1 |
p.A17T | STAD | 1 |
p.G288V | CESC | 1 |
p.E132K | CESC | 1 |
p.R704H | LGG | 1 |
p.D67N | HNSC | 1 |
p.R74Q | SKCM | 1 |
p.T106M | STAD | 1 |
p.G160V | PAAD | 1 |
p.R20H | LIHC | 1 |
p.A339T | UCEC | 1 |
p.A257T | LGG | 1 |
p.D158E | LUAD | 1 |
p.V111G | LUAD | 1 |
p.P589S | SARC | 1 |
p.R626W | ACC | 1 |
p.S316I | LGG | 1 |
p.Y429C | STAD | 1 |
p.T578M | PRAD | 1 |
p.G364R | UCEC | 1 |
p.P672T | TGCT | 1 |
p.Y562C | LUAD | 1 |
p.V111G | MESO | 1 |
p.P66R | BLCA | 1 |
p.E474K | CESC | 1 |
p.G349S | BRCA | 1 |
p.S540F | ESCA | 1 |
p.G272V | LUAD | 1 |
p.T567M | GBM | 1 |
p.R704C | COAD | 1 |
p.L731F | LUAD | 1 |
p.A53T | COAD | 1 |
p.V268M | SKCM | 1 |
p.Q460* | LUAD | 1 |
p.T718I | SKCM | 1 |
p.P185S | SKCM | 1 |
p.S324I | PAAD | 1 |
p.E262K | UVM | 1 |
p.G234D | SKCM | 1 |
p.G312S | UCEC | 1 |
p.R692C | STAD | 1 |
p.R20C | CHOL | 1 |
p.R487C | READ | 1 |
p.G272S | STAD | 1 |
p.S194R | TGCT | 1 |
p.R38K | UCEC | 1 |
p.T235A | STAD | 1 |
p.R90H | DLBC | 1 |
p.V99L | ACC | 1 |
p.R266H | COAD | 1 |
p.E557Q | BLCA | 1 |
p.R473G | LUAD | 1 |
p.T267M | COAD | 1 |
p.R503H | STAD | 1 |
p.G160D | LUAD | 1 |
p.R54H | PCPG | 1 |
p.R281H | COAD | 1 |
p.G323S | SKCM | 1 |
p.D179N | CESC | 1 |
p.G301S | LIHC | 1 |
p.C365Y | LIHC | 1 |
p.P174S | SKCM | 1 |
p.R11C | THCA | 1 |
p.D306N | SKCM | 1 |
p.R266H | THYM | 1 |
Top |
TissGeneCNV for PCSK4 |
Copy number variations of TissGene across 28 cancer types (X-axis: cancer type and Y-axis: % of CNV samples) (TCGA Gistic2_CopyNumber_Gistic2_all_data_by_genes, Gistic2 copy number data, version 2016-08-16) |
Top |
TissGeneFusions for PCSK4 |
Fusion genes including TissGene (ChimerDB 3.0, 2016-12-01 and TCGA fusion Portal 2015-12-01) |
Database | Src | Cancer type | Sample | Fusion gene | ORF | 5'-gene BP | 3'-gene BP |
Chimerdb3.0 | ChiTaRs | NA | T10978 | PCSK4-P2RX3 | chr19:1488557 | chr11:57107719 |
Top |
TissGeneNet for PCSK4 |
Co-expressed gene networks based on protein-protein interaction data (CePIN) (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) (PINA2 ppi data) |
Top |
TissGeneProg for PCSK4 |
Kaplan-Meier plots with logrank tests of overall survival (OS) using 28 cancer types (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) (TCGA clinicalMatrix, phenotype data, version 2016-04-27) * Click on the image to enlarge it in a new window. |
Kaplan-Meier plots with logrank test of relapse free survival (RFS) using 28 cancer types (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) (TCGA clinicalMatrix, phenotype data, version 2016-04-27) * Click on the image enlarge it in a new window. |
Forest plot of Cox proportional hazard ratio (HR) and 95% CI of overall survival (OS) using 28 cancer types (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) (TCGA clinicalMatrix, phenotype data, version 2016-04-27) * Click on the image enlarge it in a new window. |
Forest plot of Cox proportional hazard ratio (HR) and 95% CI of relapse free survival (RFS) using 28 cancer types (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) (TCGA clinicalMatrix, phenotype data, version 2016-04-27) * Click on the image enlarge it in a new window. |
Top |
TissGeneClin for PCSK4 |
TissGeneDrug for PCSK4 |
Drug information targeting TissGene (DrugBank Version 5.0.6, 2017-04-01) |
DrugBank ID | Drug name | Drug activity | Drug type | Drug status |
Top |
TissGeneDisease for PCSK4 |
Disease information associated with TissGene (DisGeNet, 2016-06-01) |
Disease ID | Disease name | # pubmeds | Source |
umls:C0007131 | Non-Small Cell Lung Carcinoma | 1 | BeFree |